Pure Global
NCT06337630

A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors

A Phase I Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) With Dose Expansion Cohorts in Patients With Advanced Solid Tumors
Institut Curie·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
PLX038 + Tuvusertib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Institut Curie
Location
Paris,Saint-Cloud, France
Timeline & enrollment
Phase
Phase 1
Start date
Jun 15, 2024
End date
Feb 15, 2029
Enrollment
92 participants
Primary outcome

Dose escalation step : Dose limiting toxicities (DLTs),Expansion cohorts : Best tumor response,Expansion cohorts : Serious Adverse Events (SAEs),Expansion cohorts : Adverse Events (AEs)

Summary

Phase I with a dose finding cohort, followed by expansion cohorts in pre-specified tumor
 types.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06337630
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06337630 through Pure Global AI's free database. This Phase 1 trial is sponsored by Institut Curie and is currently Not yet recruiting. The study focuses on Solid Tumor. Target enrollment is 92 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.